The Netherlands serves as Europe's gateway for medical innovation. With the European Medicines Agency (EMA) headquartered in Amsterdam and the world-class Wageningen University leading agrifood research, the demand for high-precision pathogen detection is paramount. Our systems are designed to meet the rigorous IVDR standards required by Dutch healthcare authorities.
In an era of rapid zoonotic transmission and anti-microbial resistance (AMR), our global presence ensures that Dutch labs receive the same cutting-edge technology used in the world's leading CDC facilities. We bridge the gap between Asian manufacturing efficiency and European clinical precision.
As a global leader in dairy and livestock exports, the Netherlands requires robust veterinary diagnostics. Our "One Health" approach integrates human, animal, and environmental pathogen monitoring, supporting the Dutch commitment to sustainable and safe food production.
Shenzhen BioX Medical Co., Ltd. is a professional manufacturer specializing in molecular diagnostic analysis systems, genetic testing solutions, and clinical laboratory equipment. Established in 2017, we are headquartered in Shenzhen, China—the "Silicon Valley of the East"—where we leverage advanced manufacturing and biotech innovation.
With a 9,000 square meter facility and 200+ specialists, our R&D focus is on providing scalable solutions for clinical laboratories, research institutions, and public health organizations across the Netherlands and the EU.
Automated ID/AST systems for rapid antibiotic susceptibility testing, crucial for Dutch hospitals tackling AMR (Anti-Microbial Resistance) and improving patient outcomes in ICU settings.
Detection of pathogens in wastewater and laboratory runoff, aligning with Dutch environmental regulations and the RIVM's surveillance programs for public health safety.
Specialized PCR systems for livestock pathogen detection (Avian Flu, Swine Fever) to protect the Netherlands' vital agricultural export economy.
Our commitment to the Dutch market involves a rigorous adherence to localized support and global standards:
All molecular diagnostic platforms are undergoing transition to the new EU In Vitro Diagnostic Regulation (IVDR), ensuring long-term reliability for Dutch medical practitioners.
Our 2024-2025 roadmap includes the deployment of AI-driven analytical software for real-time PCR, reducing human error and increasing the speed of pathogen identification.
Providing Dutch-language technical documentation, remote calibration services, and rapid-response spare parts logistics to ensure zero downtime in critical diagnostic workflows.
A: Yes, our systems feature an open platform design compatible with most universal PCR reagents used in European laboratories, while also offering optimized kits for maximum sensitivity.
A: We provide DDP (Delivered Duty Paid) options and work with specialized medical logistics partners to ensure safe, temperature-controlled delivery to Rotterdam, Amsterdam, or any regional Dutch hub.
A: Absolutely. We provide flexible manufacturing for Dutch companies looking to scale their proprietary molecular assays using our validated hardware platforms.
A: Typically, for standard units, we maintain a lead time of 2-4 weeks. Large-scale laboratory fit-outs are scheduled via our project management team to align with your facility's operational timeline.
BioX Medical
